

The world is racing to find safe and effective vaccines against COVID-19. And when we do, these vaccines must be made available to everyone who needs them regardless of nationality or wealth. Not only is this morally right but it is also the fastest way to end the pandemic. So as world leaders line up to make deals for COVID-19 vaccines candidates we want to know: **did this deal move us closer to, or further from, an equitable outcome?**

The Vaccine Access Test provides a framework to answer this question by evaluating deals between companies and countries using three metrics:

- ➔ **Prioritized:** Is this deal aligned with global guidelines on prioritizing allocation among at-risk populations?
- ➔ **Phased:** Does this deal allow for phased delivery of doses to ensure initial-supply is not monopolized?
- ➔ **Published:** Is the contracting processes transparent from start to finish?

Each metric is worth up to 2 points with the potential for 6 points total. **Here is how this deal stacks up.**

DEAL SUMMARY

Parties: AstraZeneca and Brazil

Date: August 11, 2020

Terms of Agreement: Brazil made a \$362 million supply and licensing deal with AZ for at least 100 million doses of the University of Oxford's vaccine. Those funds will cover the initial 100 million-dose order as well as Brazil's licensing rights to produce the vaccine at the Oswaldo Cruz Foundation if the vaccine is found effective. The new agreement builds on the drugmaker's earlier deal with Brazil in June to supply around 30 million unfinished doses of the vaccine at a price tag of \$127 million.

METRIC	SCORE	RATIONALE	<h2>Total Score: 0 out of 6</h2> <p>This deal does little to ensure the initial supply of vaccines isn't monopolized by Brazil. Subsequent deals could be improved by purchasing more closely against global population allocation guidelines and phasing delivery. AstraZeneca could also disclose a break-down of how they arrived at their unit price, and what it costs to produce the vaccine. We will also be watching to ensure further doses aren't purchased before other countries have secured deals for portions of the initial supply.</p>
Prioritized 	0	100m doses would cover nearly 24% of Brazil's population with a 2-dose regimen, exceeding the 3% initial allocation threshold and the threshold to prioritize the most vulnerable 20% population.	
Phased 	0	The deal does not include phased delivery of doses. Ideally, deals would allow for other countries to benefit from the initial supply and tier delivery of subsequent supply as it becomes available.	
Published 	0	Brazil has not listed details about the terms of deal and pricing online. AZ has not disclosed their pricing model.	



▲ Impeding Equity

Advancing Equity ▲